MX2022009781A - Metodos para estimular una respuesta antitumoral utilizando un modulador selectivo del receptor de glucocorticoides. - Google Patents
Metodos para estimular una respuesta antitumoral utilizando un modulador selectivo del receptor de glucocorticoides.Info
- Publication number
- MX2022009781A MX2022009781A MX2022009781A MX2022009781A MX2022009781A MX 2022009781 A MX2022009781 A MX 2022009781A MX 2022009781 A MX2022009781 A MX 2022009781A MX 2022009781 A MX2022009781 A MX 2022009781A MX 2022009781 A MX2022009781 A MX 2022009781A
- Authority
- MX
- Mexico
- Prior art keywords
- grm
- administration
- methods
- increased
- immune function
- Prior art date
Links
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 4
- 230000006023 anti-tumor response Effects 0.000 title 1
- 230000004936 stimulating effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 201000011510 cancer Diseases 0.000 abstract 4
- 230000036737 immune function Effects 0.000 abstract 4
- 230000028327 secretion Effects 0.000 abstract 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 230000006044 T cell activation Effects 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se describen métodos para mejorar la función inmune en un paciente con cáncer que tiene un tumor sólido. La mejora en la función inmune puede retrasar o detener el crecimiento del tumor y puede reducir la carga tumoral. Los métodos incluyen la administración de cantidades eficaces de un tratamiento contra el cáncer y un modulador del receptor de glucocorticoides no esteroideo (GRM) o GRM selectivo (SGRM). El tratamiento del cáncer puede incluir la administración de un inhibidor de puntos de control. La administración de GRM o SGRM puede inducir sensibilidad al inhibidor de puntos de control en el cáncer. La función inmune mejorada puede incluir mayor activación de las células T CD8+, mayor secreción de citocinas proinflamatorias, mayor secreción de TNFa, mayor secreción de IFN? y otros cambios en comparación con dicha activación y secreción antes de la administración de GRM. En modalidades, la función inmune mejora después de 1, 2, 3 o más días de administración de GRM. Otras características del paciente también pueden mejorarse por los métodos descritos en la presente. Los GRM incluyen azadecalina fusionada con heteroarilcetona y azadecalina octahidrofusionada. La administración de GRM incluye la administración oral de GRM.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062972442P | 2020-02-10 | 2020-02-10 | |
| PCT/US2021/017259 WO2021163058A1 (en) | 2020-02-10 | 2021-02-09 | Methods of stimulating an anti-tumor response using a selective glucocorticoid receptor modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009781A true MX2022009781A (es) | 2022-09-09 |
Family
ID=77292566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009781A MX2022009781A (es) | 2020-02-10 | 2021-02-09 | Metodos para estimular una respuesta antitumoral utilizando un modulador selectivo del receptor de glucocorticoides. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230346774A1 (es) |
| EP (1) | EP4103180A4 (es) |
| JP (2) | JP2023515781A (es) |
| KR (1) | KR20220140567A (es) |
| CN (1) | CN115397418A (es) |
| AU (1) | AU2021220763B2 (es) |
| CA (1) | CA3166901A1 (es) |
| IL (1) | IL294953A (es) |
| MX (1) | MX2022009781A (es) |
| WO (1) | WO2021163058A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240091385A1 (en) * | 2022-09-02 | 2024-03-21 | Corcept Therapeutics Incorporated | Methods of assessing selective glucocorticoid receptor modulation and of identifying and treating patients likely to benefit from glucocorticoid receptor modulation |
| US20240131020A1 (en) * | 2022-10-06 | 2024-04-25 | Corcept Therapeutics Incorporated | Formulations of glucocorticoid receptor modulators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ550362A (en) * | 2004-03-09 | 2010-06-25 | Corcept Therapeutics Inc | Fused ring azadecalin glucocorticoid receptor modulators |
| EP3111950B1 (en) * | 2012-02-24 | 2021-08-25 | The University of Chicago | Methods and compositions related to glucocorticoid receptor antagonism and prostate cancer |
| KR20180116372A (ko) * | 2016-03-01 | 2018-10-24 | 코어셉트 쎄라퓨틱스, 잉크. | 체크포인트 억제제를 강화시키기 위한 글루코코르티코이드 수용체 조정제의 용도 |
| US9943505B2 (en) * | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| SG11201908790PA (en) * | 2017-03-31 | 2019-10-30 | Corcept Therapeutics Inc | Glucocorticoid receptor modulators to treat cervical cancer |
-
2021
- 2021-02-09 CN CN202180027561.9A patent/CN115397418A/zh active Pending
- 2021-02-09 JP JP2022548708A patent/JP2023515781A/ja active Pending
- 2021-02-09 AU AU2021220763A patent/AU2021220763B2/en active Active
- 2021-02-09 KR KR1020227030946A patent/KR20220140567A/ko unknown
- 2021-02-09 EP EP21754211.7A patent/EP4103180A4/en active Pending
- 2021-02-09 IL IL294953A patent/IL294953A/en unknown
- 2021-02-09 WO PCT/US2021/017259 patent/WO2021163058A1/en active Application Filing
- 2021-02-09 MX MX2022009781A patent/MX2022009781A/es unknown
- 2021-02-09 CA CA3166901A patent/CA3166901A1/en active Pending
- 2021-02-10 US US17/793,271 patent/US20230346774A1/en active Pending
-
2024
- 2024-04-08 JP JP2024062166A patent/JP2024109557A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4103180A4 (en) | 2024-03-13 |
| CN115397418A (zh) | 2022-11-25 |
| AU2021220763A1 (en) | 2022-09-08 |
| EP4103180A1 (en) | 2022-12-21 |
| IL294953A (en) | 2022-09-01 |
| KR20220140567A (ko) | 2022-10-18 |
| JP2023515781A (ja) | 2023-04-14 |
| WO2021163058A1 (en) | 2021-08-19 |
| JP2024109557A (ja) | 2024-08-14 |
| AU2021220763B2 (en) | 2024-01-18 |
| US20230346774A1 (en) | 2023-11-02 |
| CA3166901A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009781A (es) | Metodos para estimular una respuesta antitumoral utilizando un modulador selectivo del receptor de glucocorticoides. | |
| Barth et al. | The role of adjuvant therapy in melanoma management | |
| AR004445A1 (es) | Una composicion inmunogenica, una dosis unitaria, un metodo para producir la composicion, un kit para producir la composicion, una poblacion de celulas,uso de dicha poblacion celular y una preparacion combinada | |
| Bomford | Active specific immunotherapy of mouse methylcholanthrene induced tumours with Corynebacterium parvum and irradiated tumour cells | |
| Gorelik et al. | Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor | |
| HUP0101139A2 (hu) | Porított vakcinakészítmények transzdermális beadásra | |
| Bogden et al. | Comparative study on the effects of surgery, chemotherapy, and immunotherapy, alone and in combination, on metastases of the 13762 mammary adenocarcinoma | |
| Lersch et al. | Nonspecific immunostimulation with low doses of cyclophosphamide (LDCY), thymostimulin, and Echinacea purpurea extracts (echinacin) in patients with far advanced colorectal cancers: preliminary results | |
| DE69030880D1 (de) | Zusammensetzung zur Stimulierung des Immunsystems | |
| MX2021001762A (es) | Metodo y composicion para estimular la respuesta inmunitaria. | |
| JP6440360B2 (ja) | 経皮投与用ワクチン組成物 | |
| MXPA01007657A (es) | Vacunacion no invasiva a traves de la piel. | |
| KR100392582B1 (ko) | 면역치료제및이의용도 | |
| Takimoto et al. | Potentiation of cytotoxic activity in naive and tumor-bearing mice by oral administration of hot-water extracts from Agaricus brazei fruiting bodies | |
| ES2144426T3 (es) | Terapia genica linfoquimica del cancer en combinacion con antigenos tumorales. | |
| EP1723963A3 (en) | Hapten-conjugated tumour cells | |
| CA2354046A1 (en) | New cancer treatments | |
| IL102460A (en) | Method for enhancing the immunotherapeutic activity of lymphocytes to decrease the tumor burden by stimulation of lymphocytes in vitro in the presence of anti-cd3-antibody and by co-administration of il-2, kits containing such enhanced lymphocytes and their use in preparation of a medicament for cancer therapy | |
| PT904067E (pt) | Dextrometorfan como agente antitussico administrado transdermicamente | |
| AU2003212170A1 (en) | Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof | |
| Choi et al. | The function of memory CD8+ T cells in immunotherapy for human diseases | |
| Hersh et al. | BCG vaccine and its derivatives: potential, practical considerations, and precautions in human cancer immunotherapy | |
| PL295273A1 (en) | Method of obtaining a preparation capable to retard the synthesis of endogenous cytotoxic cytokinins | |
| ES2039236T3 (es) | Metodo para preparar una composicion terapeutica de interlenquina-2 y/o interferon-beta y factor de necrosis tumoral. | |
| WO2022174064A3 (en) | Therapeutic composition and method combining multiplex immunotherapy with cancer vaccine for the treatment of cancer |